Adlai Nortye Group Financial Statements
NASDAQ: ANLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
15.62+0.11 (+0.71%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Adlai Nortye Group revenue and earnings
Adlai Nortye Group reported a net loss of $51.9 million, compared with a loss of $109.2 million a year earlier. Diluted earnings per share came in at -$0.54.
Summary generated from market data by MetaCap's automated system. Methodology
Adlai Nortye Group income statement (annual)
| Fiscal year (USD) | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 |
|---|---|---|---|---|
| Revenue | — | 5.00M | — | 45.73M |
| Revenue growth (YoY) | — | — | — | — |
| Research & Development | 44.91M | 58.15M | 54.49M | 42.10M |
| Operating Income | -52.93M | -72.55M | -67.27M | -8.65M |
| Interest Expense | 1.94M | 791.00K | 433.00K | 1.34M |
| Pretax Income | -51.87M | -109.23M | -58.79M | -56.68M |
| Income Tax | — | 643.00K | — | — |
| Net Income | -51.87M | -109.23M | -58.79M | -56.68M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -0.54 | -2.52 | -2.31 | -2.23 |
| EPS (Diluted) | -0.54 | -2.52 | -2.31 | -2.23 |
| Shares Outstanding (Basic) | 95.78M | 43.34M | 25.44M | 25.44M |
| Shares Outstanding (Diluted) | 95.78M | 43.34M | 25.44M | 25.44M |
| EBITDA | -52.42M | -72.09M | -66.66M | — |
| Operating Margin | — | -1451.02% | — | -18.91% |
| Net Margin | — | -2184.56% | — | -123.95% |
This table shows 4 annual periods of Adlai Nortye Group's income statement, from FY 2024 back to FY 2021, across 14 line items including revenue, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow ANL's reporting calendar. What is a income statement?